Skip to main content
Premium Trial:

Request an Annual Quote

Informax Gets $10 Million from Amersham Pharmacia

NEW YORK, Sept 6  Amersham Pharmacia Biotech said on Wednesday it had invested $10 million in InforMax and also announced a strategic collaboration with the bioinformatics company.

The deal represents the largest collaboration for InforMax of Rockville, Md., to date.

Under the terms of the deal Amersham, the Piscataway, N.J.-based life sciences division of Nycomed Amersham (NYSE: NYE; LSE: NAM), and InforMax will work together to expand the capability of InforMax’s GenoMax bioinformatics product.

The companies plan on creating a data analysis system that will allow pharmaceutical companies to merge and analyze genomics, pharmacogentics, proteomics and drug screening data.

The companies will share the proceeds from marketing and distributing the new product.

“Our goal is to expand our bioinformatics business by integrating our diverse high throughput platforms into a higher value proposition for our pharmaceutical industry customers,” Andrew Whiteley, vice president of bioinformatics at Amersham Pharmacia Biotech, said in a statement.

Amersham could not immediately be reached for comment.

A spokesman for InforMax declined to comment on the deal, saying the company is in a quiet period in the run up to its planned initial public offering on the Nasdaq.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.